Skip to main content

Table 4 Intervention issues of top five medications

From: Development of clinical pharmacy services for intensive care units in Korea

Medication

Vancomycin

Famotidine

Ranitidine

Meropenem

Theophylline

Intervention Issue

     

Clinical pharmacokinetic service

201 (85.2)

0 (0.0)

0 (0.0)

0 (0.0)

20 (47.6)

Dosage increment or dosing interval decrement

5 (2.1)

4 (6.5)

2 (3.4)

13 (22.8)

5 (11.9)

Dosage decrement or dosing interval increment

8 (3.4)

42 (67.7)

36 (62.1)

32 (56.1)

1 (2.4)

Medication form

1 (0.4)

0 (0.0)

0 (0.0)

0 (0.0)

1 (2.4)

Dosing time or dose

19 (8.1)

4 (6.5)

5 (8.6)

8 (14.0)

10 (23.8)

Dosing route

1 (0.4)

3 (4.8)

1 (1.7)

0 (0.0)

1 (2.4)

Discontinuation of medication

0 (0.0)

3 (4.8)

2 (3.4)

0 (0.0)

1 (2.4)

Medication change

0 (0.0)

1 (1.6)

0 (0.0)

0 (0.0)

0 (0.0)

Adverse drug reaction

1 (0.4)

5 (8.1)

11 (19.0)

2 (3.5)

1 (2.4)

Fluid compatibility

0 (0.0)

0 (0.0)

0 (0.0)

1 (1.8)

0 (0.0)

Drug interaction

0 (0.0)

0 (0.0)

0 (0.0)

1 (1.8)

1 (2.4)

Others

0 (0.0)

0 (0.0)

1 (1.7)1

0 (0.0)

1 (2.4)

Total

236 (100.0)

62 (100.0)

58 (100.0)

57 (100.0)

42 (100.0)

  1. Values are expressed as the number (percentage).
  2. 1Drug Omission.
  3. P-value < 0.001.